DFW Friends Logo

Herpes Vaccines: Where Research Stands in 2026

“Is there a herpes vaccine yet?” is one of the most common questions newly diagnosed people ask. The short answer as of 2026: not yet for herpes simplex, but research continues. There is, however, a highly effective vaccine for HPV. This update from DFW Friends, a free, private social group for adults 21+ in Dallas–Fort Worth, explains what exists today and what is still in testing.

No Approved Vaccine for HSV-1 or HSV-2

No vaccine is approved anywhere in the world to prevent or treat herpes simplex. Scientists have chased one for decades, and the road is littered with near misses. GSK’s Herpevac, tested in thousands of women, failed to protect against HSV-2 and was shelved. Genocea’s GEN-003 looked promising in mid-stage studies but ran out of funding.

Why Herpes Is So Hard to Vaccinate Against

HSV is a master at dodging the immune system. It hides inside nerve cells, dials down warning signals and uses its surface proteins to blunt both antibodies and T cells. Older vaccines often produced immunity that was too narrow or faded too fast, especially at the skin and mucous membranes where infection begins. The stakes are real: besides stigma and outbreaks, herpes can rarely cause dangerous neonatal infections in newborns.

Two Kinds of Herpes Vaccines

A therapeutic shot would matter most to people already living with herpes, which is why setbacks in that category get so much attention.

Recent Setbacks: GSK and Moderna

In 2024, GSK said its therapeutic candidate (GSK3943104) would not move into Phase 3 after interim data disappointed, and the final Phase 2 readout in 2025 confirmed it missed its main goal of reducing recurrences. Moderna’s mRNA-1608, a therapeutic mRNA vaccine, finished a Phase 1/2 study of about 300 adults in April 2025. Interim results showed it was well tolerated with a trend toward fewer recurrences, but Moderna told investors in November 2025 that the program was ending before Phase 3, citing pipeline priorities rather than a safety problem.

Candidates Still Being Studied

BioNTech BNT163: an mRNA preventive vaccine built on University of Pennsylvania research that teaches the body to recognize three HSV-2 surface proteins (gC2, gD2 and gE2). Its Phase 1 trial enrolled about 318 volunteers, including a group with recurrent genital herpes, and is active but no longer recruiting, with primary completion listed for October 2026. Early 2026 conference data reported mostly mild-to-moderate side effects and antibody responses against HSV-2, but no evidence yet on whether it prevents infection. Full results will help decide whether a Phase 2 study follows. It is now the only HSV shot from a major drug company still in human testing.

Rational Vaccines RVx-201: a live-attenuated therapeutic candidate weakened through changes to a viral protein called ICP0. Guinea pig studies showed protection against facial, eye and genital disease. The UK granted it an Innovation Passport in 2021, and the company is working toward a first formal UK therapeutic trial while describing its pipeline as preclinical. It is offered privately at clinics outside the U.S., but it is not approved by the FDA or any major regulator, and no large controlled trial results have been published.

Delta gD-2 (ΔgD-2): a single-cycle HSV-2 virus from Albert Einstein College of Medicine that can enter cells once but cannot spread. Mouse studies showed strong, long-lasting protection against both HSV types. Its licensee, X-Vax, filed for bankruptcy in 2023, and no human trial is registered.

EXD-12: a live-attenuated candidate from Excell Biotech aimed at both HSV-1 and HSV-2. It never reached human trials and is listed as discontinued at the preclinical stage.

Even a strong candidate would need years of larger trials before reaching a doctor’s office in Dallas or anywhere else.

A New Treatment Option, Not a Vaccine

On October 9, 2026, the FDA approved pritelivir (Hovilpri), a new class of oral antiviral, for immunocompromised adults whose herpes sores don’t respond to acyclovir, valacyclovir or famciclovir. It is not a vaccine or a cure, but it is the first new herpes antiviral class in decades.

A Word of Caution About “Vaccine” Claims

Some websites and clinics sell unapproved herpes “vaccines” or “cures.” These products have not been proven safe or effective. Unregulated self-experiments in the past have ended badly. Stick with information from ClinicalTrials.gov, the CDC, NIH and your own provider. If you want to help research, you can search ClinicalTrials.gov for studies; Texas, including the DFW area, often has trial sites.

The HPV Vaccine Works, and Works Well

Unlike herpes, HPV has a proven vaccine. Gardasil 9 protects against nine HPV types that cause most HPV-related cancers and genital warts. The CDC recommends it routinely at ages 11 to 12, and it can be given as early as 9. Catch-up vaccination is recommended through age 26. Adults 27 to 45 who weren’t vaccinated can talk with their provider about whether it makes sense for them, and the FDA has approved it for that age range.

Since the vaccine was introduced, infections with the targeted HPV types have dropped sharply among young women in the U.S., and cervical precancers are declining too. Even if you already have one HPV type, the vaccine may still protect you against others.

Stay Hopeful, Stay Connected

Science is moving, but you don’t have to wait for a breakthrough to enjoy life. DFW Friends is a free, non-dating social group with private events across the Metroplex. Email info@dfwfriends.org to learn how to join us.

For informational purposes only, not medical advice. Talk to your healthcare provider.

Sources